Streetbeat News

Earnings

UNH

UnitedHealth Group Inc (NYSE: UNH) reported its second-quarter results, surpassing earnings expectations. Analysts from RBC Capital Markets, Goldman Sachs, Truist Securities, Cantor Fitzgerald, and Oppenheimer provided positive ratings and raised price targets, citing various factors for potential improvement in 2025.

Portfolio Pulse from Priya Nigam

July 17, 2024 | 7:05 pm

LNG

Five analysts have provided ratings for Cheniere Energy (NYSE:LNG) over the past quarter, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $202.4. Cheniere Energy faces challenges with revenue growth and net margin but shows strong return on equity.

Portfolio Pulse from Benzinga Insights

July 17, 2024 | 7:02 pm

AIN

Analysts' ratings for Albany Intl (NYSE:AIN) over the last quarter show a mix of bullish and bearish sentiments. The average 12-month price target has decreased to $97.2 from $104.80. Key analysts from firms like Truist Securities, B of A Securities, JP Morgan, and TD Cowen have lowered their price targets. Albany Intl has shown strong financial performance with a 16.44% revenue growth rate, 8.71% net margin, and a low debt-to-equity ratio of 0.45.

Portfolio Pulse from Benzinga Insights

July 17, 2024 | 7:00 pm

PRPO

Precipio shares are trading higher after the company reported a Q2 revenue beat.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 6:45 pm

ADTX

AEHR

ASLN

FIVE

SAVA

SHIM

SYF

U.S. stocks traded mixed with the Dow up 0.53% and the NASDAQ down 2.51%. Synchrony Financial posted better-than-expected earnings. Aditxt, Aehr Test Systems, and Shimmick Corporation saw significant stock price increases, while ASLAN Pharmaceuticals, Cassava Sciences, and Five Below experienced notable declines.

Portfolio Pulse from Avi Kapoor

July 17, 2024 | 6:36 pm

KLAC

Recent options activity for KLA (NASDAQ:KLAC) shows a bullish stance among significant investors, with 41% of trades being bullish and 31% bearish. The trading activity suggests a price range of $680 to $1140 over the next three months. KLA's stock is currently down by 8.04% at $797.42, with an earnings announcement expected in 7 days. Analysts have mixed ratings with an average target price of $935.

Portfolio Pulse from Benzinga Insights

July 17, 2024 | 6:30 pm

VFC

VF Corporation (NYSE:VFC) shares are trading higher after announcing the sale of its Supreme brand to EssilorLuxottica for $1.5 billion in cash. The sale is expected to be dilutive to VF's earnings per share in fiscal year 2025. Supreme contributed $538 million in revenue and $166 million in operating income during VF's 2024 fiscal year. VF shares are moving above their 50-day moving average, and the company is set to report its first-quarter 2025 results on Aug. 6.

Portfolio Pulse from Erica Kollmann

July 17, 2024 | 6:28 pm

AMD

ARM

ASML

JNJ

MAGS

NVDA

SCHW

SMH

SOXX

TSM

The Nasdaq 100 experienced its worst day in 11 months, driven by a broad selloff in semiconductor stocks following news of the Biden administration's accelerated export restrictions to China. Major chipmakers like ASML Holding and Nvidia saw significant declines, impacting related ETFs and indices. The S&P 500 and Russell 2000 also fell, while the Dow Jones rose. Other notable stock movements included significant drops in AMD, TSM, ARM, and SCHW, while JNJ rallied on strong earnings.

Portfolio Pulse from Piero Cingari

July 17, 2024 | 6:27 pm

FDMT

4D Molecular Therapeutics (NASDAQ: FDMT) released interim 24-week data from its Phase 2 PRISM trial for wet AMD, showing promising results in reducing anti-VEGF injections and improving visual outcomes. The company plans to update the Phase 3 trial design in September 2024 and start the first Phase 3 trial in early 2025. Despite the positive data, FDMT shares are down 35.7% to $17.19.

Portfolio Pulse from Vandana Singh

July 17, 2024 | 6:22 pm

JNJ

Johnson & Johnson (NYSE:JNJ) reported strong Q2 results with a 4.3% YoY topline growth to $22.45 billion, surpassing expectations. The medtech and innovative medicine divisions showed significant progress, although one-time charges impacted net earnings. J&J raised its full-year operational sales guidance but lowered EPS guidance due to acquisition costs.

Portfolio Pulse from Upwallstreet

July 17, 2024 | 6:05 pm